Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Corvus Pharmaceuticals, Inc. (CRVS : NSDQ)
 
 • Company Description   
Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.

Number of Employees: 28

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.04 Daily Weekly Monthly
20 Day Moving Average: 230,680 shares
Shares Outstanding: 46.55 (millions)
Market Capitalization: $48.65 (millions)
Beta: 1.06
52 Week High: $9.54
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.82% -17.68%
12 Week -43.21% -36.17%
Year To Date -56.64% -47.03%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
863 Mitten Road Suite102
-
BURLINGAME,CA 94010
USA
ph: 650-900-4520
fax: -
jcoloma@corvuspharma.com http://www.corvuspharma.com
 
 • General Corporate Information   
Officers
Richard A. Miller - President; Chief Executive Officer and Director
Leiv Lea - Chief Financial Officer
Ian T. Clark - Director
Linda S. Grais - Director
Edith P. Mitchell - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 221015100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/01/22
Share - Related Items
Shares Outstanding: 46.55
Most Recent Split Date: (:1)
Beta: 1.06
Market Capitalization: $48.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.88 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/01/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.54
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 47.06%
vs. Previous Quarter: 10.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -41.15
12/31/21 - -44.00
09/30/21 - -47.94
ROA
03/31/22 - -36.37
12/31/21 - -38.66
09/30/21 - -41.67
Current Ratio
03/31/22 - 6.95
12/31/21 - 7.36
09/30/21 - 6.97
Quick Ratio
03/31/22 - 6.95
12/31/21 - 7.36
09/30/21 - 6.97
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.93
12/31/21 - 2.09
09/30/21 - 2.48
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©